{"entity":{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","aka":["CCR","NCI intramural"],"tldr":"The NCI's own laboratories and clinic at the NIH Clinical Center, home of Rosenberg's cell therapy branch, the HPV vaccine and lymphoma genomics.","summary":"The Center for Cancer Research is the NCI's intramural research programme, with laboratories in Bethesda and Frederick and a clinical arm at the NIH Clinical Center, the largest hospital in the world devoted to research, where patients on protocol are treated free of charge. Steven Rosenberg's Surgery Branch produced the first effective cancer immunotherapy (high-dose IL-2), the first gene-modified T cells (1990), TIL therapy and neoantigen-directed TCR therapy; Douglas Lowy and John Schiller invented the virus-like-particle technology behind HPV vaccines; Louis Staudt's lymphoma genomics defined the ABC and GCB subtypes of DLBCL. The Pediatric Oncology Branch (Brigitte Widemann, Nirali Shah) led selumetinib for NF1 and CD22 CAR-T, and James Gulley and Raffit Hassan run immunotherapy and mesothelin programmes. Most CCR trials are open to referral from any physician.","asOf":"2026-09-09","links":[{"label":"Center for Cancer Research","url":"https://ccr.cancer.gov"},{"label":"CCR clinical trials","url":"https://ccr.cancer.gov/clinical-trials"},{"label":"NIH Clinical Center","url":"https://clinicalcenter.nih.gov"}],"tags":[],"related":[],"cancers":["melanoma","dlbcl","cervical","mesothelioma"],"sections":["cell-therapy","immunotherapy"],"technologies":["til-therapy","tcr-t","car-t","hpv-vaccine","cytokine-therapy"],"targets":["cd22","mesothelin"],"drugs":["aldesleukin"],"companies":[],"institutions":["nci","frederick-national-lab"],"pathways":[],"terms":[],"trials":[],"people":["steven-rosenberg","louis-staudt","douglas-lowy","james-gulley","brigitte-widemann","nirali-shah","raffit-hassan","senthil-muthuswamy","wyndham-wilson"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bethesda, MD","country":"US","lat":39.002,"lng":-77.105,"institutionType":"government","website":"https://ccr.cancer.gov","programs":["Surgery Branch (TIL, TCR-T)","HPV vaccine science","Lymphoid malignancies","Pediatric Oncology Branch","NIH Clinical Center trials"]},"route":"/institutions/nci-ccr/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"},{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"target":[{"id":"cd22","kind":"target","name":"CD22","route":"/targets/cd22/"},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"}],"institution":[{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","route":"/institutions/rutgers-cinj/"}],"person":[{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/"},{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/"},{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/"},{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/"},{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/"},{"id":"raffit-hassan","kind":"person","name":"Raffit Hassan","route":"/people/raffit-hassan/"},{"id":"senthil-muthuswamy","kind":"person","name":"Senthil K. Muthuswamy","route":"/people/senthil-muthuswamy/"},{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/"},{"id":"wyndham-wilson","kind":"person","name":"Wyndham H. Wilson","route":"/people/wyndham-wilson/"}],"paper":[{"id":"paper-royal-ipilimumab-pancreatic-j-immunother-2010","kind":"paper","name":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","route":"/key-papers/paper-royal-ipilimumab-pancreatic-j-immunother-2010/"}]}}